RZLT
Rezolute, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.59
+1.21%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.0x
Market Cap
$442.44M
MomentumView details →
1D Return
+1.21%
YTD Return
+94.70%
RSI (14)
45.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−4.0x
Market Cap
$442.44M
RSI (14)
45.3
MomentumView details →
1D Return
+1.21%
YTD Return
+94.70%
SummaryUpdated Mar 1, 2026
Rezolute, Inc. (NASDAQ:RZLT) is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Redwood City, California. Originally incorporated as AntriaBio, Inc., the company rebranded to Rezolute in December 2017 to better reflect its focus on developing transformative therapies for metabolic diseases. The company went public in January 2013 and has since dedicated its efforts to addressing rare and complex conditions associated with chronic glucose imbalance, particularly targeting ultra-rare pediatric genetic disorders and diabetic complications.
Similar companies
Latest newsMore news →
Bank of America Corp DE reduced its stake in Rezolute, Inc. by 31.3% during the quarter, selling 1,354,699 shares, according to its Form 13F filing.11d agoRezolute, Inc. reported an interim update from its ongoing Phase 3 upLIFT study evaluating ersodetug in patients with tumor hyperinsulinism.94d ago